|1.||Kaverina, N V: 4 articles (01/2007 - 03/2002)|
|2.||Lyskovtsev, V V: 3 articles (01/2007 - 01/2003)|
|3.||Popova, E P: 3 articles (01/2007 - 01/2003)|
|4.||Colombo, Jennifer M: 1 article (11/2013)|
|5.||Schurman, Jennifer Verrill: 1 article (11/2013)|
|6.||Friesen, Craig A: 1 article (11/2013)|
|7.||Neilan, Nancy A: 1 article (11/2013)|
|8.||Biggio, Giovanni: 1 article (07/2012)|
|9.||Sanna, Enrico: 1 article (07/2012)|
|10.||Butterworth, Roger F: 1 article (07/2012)|
01/01/2005 - "Nibentan is highly effective in persistent atrial fibrillation. "
01/01/2006 - "Nibentan has proved to be effective in preventing the vagotonic atrial fibrillation."
01/01/2008 - "To study efficacy and safety of using a domestic anti-arrhythmic drug nibentan for arresting acute atrial fibrillation. "
07/01/2000 - "The aim of this study was to investigate the effects of nibentan using a canine model of vagally sustained atrial fibrillation (AF). "
01/01/2008 - "The criterion of efficacy was atrial fibrillation conversion into the sinus rhythm within 24 hours after injection of a total nibentan dose. "
|2.||Atrial Flutter (Flutter, Atrial)
07/01/2000 - "Nibentan, a new class III antiarrhythmic drug, is highly effective in patients with atrial flutter and fibrillation. "
01/01/2007 - "The aim of the study was to compare the efficacy and safety of pharmacological cardioversion (PC) by nibentan, a class III antiarrhythmic agent, and electrical cardioversion (EC) in patients with persisting atrial fibrillation (AFib) and atrial flutter (AFI) receiving basic antiarrhythmic therapy. "
01/01/1998 - "The clinical trial of nibentan shows that the drug is highly effective (in 70-100% of cases) in patients with atrial flutter and fibrillation and in those with supraventricular tachycardia and it is less effective in suppressing ventricular premature contractions and tachycardia. "
01/01/2005 - "Mean dose of nibentan was 0.119+/-0.02 mg/kg. Proarrhythmic effects (paroxysmal or nonsustained polymorphic ventricular tachycardia) and substantial suppression of sinus rhythm automatism were registered in 3 and 3 patients, respectively. "
01/01/2008 - "Nibentan in a dose 0.125 mg/kg demonstrated high efficacy (91.9%) and sufficient safety (incidence of polymorphic ventricular tachycardia 2.4%) including patients taking other antiarrhythmic drugs. "
|1.||Potassium Channels (Potassium Channel)
|2.||Magnesium Sulfate (Sulfate, Magnesium)
|3.||N,N- dicyclohexylamide- N'- (3- diethylaminopropyl)- N- (N- nitrobenzoyl) aminoacetic acid hydroxyoxalate
|4.||Sotalol (Sotalol Hydrochloride)
|5.||Measles-Mumps-Rubella Vaccine (MMR Vaccine)
|6.||Succinic Acid (Succinate)
|10.||Etidronic Acid (HEDP)
|1.||Electric Countershock (Cardioversion)